[{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"b830c833-61a0-434d-8a29-24074697ffb9","acronym":"DURAFAK","url":"https://clinicaltrials.gov/study/NCT05512208","created_at":"2022-08-23T14:55:32.872Z","updated_at":"2025-02-25T15:27:34.112Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib","source_id_and_acronym":"NCT05512208 - DURAFAK","lead_sponsor":"University of Oklahoma","biomarkers":" BRAF • NF1 • RAS","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF • NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/06/2023","start_date":" 02/06/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-02-10"},{"id":"713cf312-05ff-4ada-845c-c46ae3aa0c4a","acronym":"RAMP 203","url":"https://clinicaltrials.gov/study/NCT05074810","created_at":"2021-10-12T14:52:57.167Z","updated_at":"2025-02-25T16:53:53.800Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","source_id_and_acronym":"NCT05074810 - RAMP 203","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 04/12/2022","start_date":" 04/12/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-02-04"},{"id":"c140a8b8-ac68-4df9-988d-ebe6e54e87b6","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT06194929","created_at":"2024-01-08T19:20:11.355Z","updated_at":"2025-02-25T17:32:44.459Z","phase":"Phase 1/2","brief_title":"Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma","source_id_and_acronym":"NCT06194929 - DETERMINE","lead_sponsor":"University of Utah","biomarkers":" NF1 • RAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation","tags":["NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Braftovi (encorafenib) • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 03/07/2024","start_date":" 03/07/2024","primary_txt":" Primary completion: 01/15/2028","primary_completion_date":" 01/15/2028","study_txt":" Completion: 01/15/2030","study_completion_date":" 01/15/2030","last_update_posted":"2025-01-30"},{"id":"bca1dafe-5b6f-43a8-b486-61c7b69a4e9d","acronym":"5G-RUBY","url":"https://clinicaltrials.gov/study/NCT06630260","created_at":"2025-02-25T19:12:02.371Z","updated_at":"2025-02-25T19:12:02.371Z","phase":"Phase 1/2","brief_title":"5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours","source_id_and_acronym":"NCT06630260 - 5G-RUBY","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 11/15/2024","start_date":" 11/15/2024","primary_txt":" Primary completion: 09/30/2029","primary_completion_date":" 09/30/2029","study_txt":" Completion: 09/30/2030","study_completion_date":" 09/30/2030","last_update_posted":"2025-01-22"},{"id":"30dba036-f8f6-4cfe-919b-a3ae6b2489da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05375994","created_at":"2022-05-17T12:54:08.747Z","updated_at":"2025-02-25T14:16:58.488Z","phase":"Phase 1/2","brief_title":"Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients","source_id_and_acronym":"NCT05375994","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • Avmapki (avutometinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 12/24/2024","primary_completion_date":" 12/24/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-11-12"},{"id":"ede642e0-5e2d-45e3-a39c-e3011badaeb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05200442","created_at":"2022-01-20T14:53:44.383Z","updated_at":"2024-07-02T16:35:06.388Z","phase":"Phase 1/2","brief_title":"A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer","source_id_and_acronym":"NCT05200442","lead_sponsor":"University of Chicago","biomarkers":" PD-L1 • KRAS • MSI","pipe":" | ","alterations":" KRAS mutation • MSI-H/dMMR","tags":["PD-L1 • KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Avmapki (avutometinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 08/22/2022","start_date":" 08/22/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-05-02"},{"id":"f14e50a7-0299-4bd6-adff-9bd98c8ffea6","acronym":"DDU RAF/MEK","url":"https://clinicaltrials.gov/study/NCT02407509","created_at":"2021-01-17T17:47:34.394Z","updated_at":"2024-07-02T16:35:13.413Z","phase":"Phase 1","brief_title":"Phase I Trial of VS-6766 Alone and in Combination With Everolimus","source_id_and_acronym":"NCT02407509 - DDU RAF/MEK","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Avmapki (avutometinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 06/17/2013","start_date":" 06/17/2013","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-03-21"},{"id":"a908832d-a81e-40f3-9e03-9eb6223d1ad7","acronym":"RAMP-202","url":"https://clinicaltrials.gov/study/NCT04620330","created_at":"2021-01-19T20:34:21.364Z","updated_at":"2024-07-02T16:35:23.520Z","phase":"Phase 2","brief_title":"A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04620330 - RAMP-202","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • KRAS G12V • KRAS G12","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 12/31/2020","start_date":" 12/31/2020","primary_txt":" Primary completion: 08/29/2023","primary_completion_date":" 08/29/2023","study_txt":" Completion: 12/12/2023","study_completion_date":" 12/12/2023","last_update_posted":"2024-01-12"},{"id":"8e6c072f-03d0-46ac-aee1-01fb748c8eb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05608252","created_at":"2022-11-08T15:56:59.631Z","updated_at":"2024-07-02T16:35:29.537Z","phase":"Phase 1/2","brief_title":"VS-6766+Abema+Fulv in Met HR+/HER- BC","source_id_and_acronym":"NCT05608252","lead_sponsor":"Adrienne G. Waks","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • Avmapki (avutometinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 02/23/2023","start_date":" 02/23/2023","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-11-13"},{"id":"0f0b0890-fa2b-48fb-a929-8a1bc66f161c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06104488","created_at":"2023-10-27T17:14:00.798Z","updated_at":"2024-07-02T16:35:31.349Z","phase":"Phase 1","brief_title":"A Study of Avutometinib for People With Solid Tumor Cancers","source_id_and_acronym":"NCT06104488","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KRAS • NRAS • HRAS • NF1 • PTPN11","pipe":" | ","alterations":" NF1 mutation","tags":["KRAS • NRAS • HRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/20/2023","start_date":" 10/20/2023","primary_txt":" Primary completion: 10/20/2029","primary_completion_date":" 10/20/2029","study_txt":" Completion: 10/20/2029","study_completion_date":" 10/20/2029","last_update_posted":"2023-10-27"},{"id":"7f628768-e4c2-43a5-8398-ff578bfae908","acronym":"","url":"https://clinicaltrials.gov/study/NCT03681483","created_at":"2021-01-18T18:03:23.213Z","updated_at":"2024-07-02T16:35:34.912Z","phase":"Phase 1","brief_title":"RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer","source_id_and_acronym":"NCT03681483","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-10-03"},{"id":"2188e1a4-494f-4dad-8033-4ac6b374cbbc","acronym":"FRAME","url":"https://clinicaltrials.gov/study/NCT03875820","created_at":"2021-01-17T17:43:26.582Z","updated_at":"2024-07-02T16:35:43.556Z","phase":"Phase 1","brief_title":"Phase I Trial of Defactinib and VS-6766.","source_id_and_acronym":"NCT03875820 - FRAME","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12V • RAS mutation • KRAS G12","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12V • RAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 12/12/2017","start_date":" 12/12/2017","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2023-07-10"}]